MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Home・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Open

SectorHealthcare

27.09 2.54

Buy Sell

Overview

Share price change

24h

Current

Min

26.5

Max

27.37

Key metrics
By Trading Economics
Income	-5.8M 40M
Sales	16M 200M
P/E Sector Avg	8.859 35.739
EPS	0.92
Profit margin	19.839
Employees	268
EBITDA	3M 59M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+63.82% upside

Dividends
By Dow Jones
Next Earnings	28 Oct 2025

Market Stats
By TradingEconomics
Market Cap	-451M 1.6B
Previous open	24.55
Previous close	27.09

News Sentiment

By Acuity

58%

42%

314 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Oct 2025, 23:30 UTC

Hot Stocks

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 Oct 2025, 21:21 UTC

Earnings

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 Oct 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 Oct 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 Oct 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 Oct 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 Oct 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 Oct 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 Oct 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 Oct 2025, 22:54 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Scales's JV Buyout Lauded by Bull -- Market Talk

2 Oct 2025, 22:54 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Forex and Fixed Income Roundup: Market Talk

2 Oct 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 Oct 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Oct 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 Oct 2025, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

2 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 Oct 2025, 20:49 UTC

Acquisitions, Mergers, Takeovers

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 Oct 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 Oct 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 Oct 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 Oct 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 Oct 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 Oct 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 Oct 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 Oct 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 Oct 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 Oct 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 Oct 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 Oct 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 Oct 2025, 18:43 UTC

Acquisitions, Mergers, Takeovers

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

63.82% upside

12 Months Forecast

Average 44.1 USD 63.82%

High 62 USD

Low 31 USD

Based on 11 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

314 / 371 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.